Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, reported positive top-line results from the phase IIb SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, the company’s first-in-class, oral Selective Inhibitor of Nuclear Export compound, in patients with relapsed or refractory diffuse large B-cell lymphoma after at least two prior multi-agent therapies and who are ineligible for transplantation, including high dose chemotherapy with stem cell rescue.
The National Cancer Registries Program, or NPCR, is a relatively small but highly impactful 33-year-old CDC program that gauges disparities in cancer and tracks progress against the disease. So, why was it left out of the Trump administration’s preliminary budget?
